Quintrio
Home

LABORATORY ANALYTICAL INSTRUMENTS

Illumina Inc

ILMN

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Last trade $201.45
Day change +$3.45 (+1.74%)
Day range $196.55 – $201.59
Volume 999,966
Market cap $29.94B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$29.94B
Price / earnings
33.45×
Price / book
9.52×
Price / sales
6.6×
EV / sales
6.71×
EV / EBITDA
24.41×

Profitability

Earnings per share
$5.92
Return on assets
13.14%
Return on equity
28.46%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.57×
Current ratio
2.63×
Quick ratio
2.05×
Cash ratio
1.12×

Cash flow

Price / cash flow
24.34×
Price / free cash flow
28.32×
Free cash flow
$1.06B

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ILMN, quarterly periods
Line itemQ3 FY2026 Sep 27, 2026Q2 FY2026 Jun 28, 2026Q1 FY2026 Mar 29, 2026Q4 FY2025 Dec 28, 2025Q3 FY2025 Sep 28, 2025Q2 FY2025 Jun 29, 2025Q1 FY2025 Mar 30, 2025Q4 FY2024 Dec 29, 2024
Revenue$1.13B$1.16B$1.09B$1.16B$1.08B$1.06B$1.04B$1.1B
Cost of revenue$299M$389M$370M$400M$351M$364M$358M$376M
Gross profit$830M$770M$721M$759M$733M$695M$683M$728M
Selling, general and administrative$281M$273M$272M$309M$277M$234M$267M$279M
Research and development$244M$252M$240M$239M$229M$247M$252M$256M
Total operating expenses$525M$525M$512M$558M$506M$481M$519M$553M
Operating income$305M$245M$209M$201M$227M$214M$164M$175M
Interest expense-$24M-$24M-$24M-$26M-$25M-$25M-$25M-$25M
Income before taxes$264M$260M$157M$377M$220M$306M$182M$187M
Income taxes$44M$53M$23M$43M$70M$71M$51M$0
Net income$220M$207M$134M$334M$150M$235M$131M$187M
Net income attributable to common shareholders$220M$207M$134M$334M$150M$235M$131M$187M
EBITDA$414M$278M$278M$277M$328M$248M$233M$264M
Basic earnings per share$1.46$1.37$0.88$2.21$0.98$1.49$0.83$1.18
Diluted earnings per share$1.43$1.35$0.87$2.17$0.98$1.49$0.82$1.18

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

Decoding Healthcare ETFs: Different Sectors, Different Strategies

The article compares two healthcare ETFs: RSPH (Invesco S&P 500 Equal Weight Healthcare ETF) and XBI (State Street SPDR S&P Biotech ETF). RSPH offers broader healthcare sector diversification with lower volatility and higher dividend yield (0.56%), while XBI provides concentrated biotech exposure with higher short-term returns (39.6% 1-year) but steeper drawdowns (53.2% max). RSPH is recommended for conservative investors seeking stability, while XBI suits those with higher risk tolerance seeking biotech-specific growth.

Zacks Investment Research

REGN vs. ILMN: Which Stock Is the Better Value Option?

A comparison of Regeneron (REGN) and Illumina (ILMN) in the biomedical and genetics sector reveals that Regeneron presents a better value opportunity. REGN has a Zacks Rank of #2 (Buy) with improving earnings outlook, a forward P/E of 15.74, and a Value grade of B. ILMN has a Zacks Rank of #3 (Hold) with a forward P/E of 44.00 and a Value grade of D, making it significantly more expensive on multiple valuation metrics.

Zacks Investment Research

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

The First Trust NYSE Arca Biotechnology ETF (FBT) is reviewed as a passively managed fund offering broad exposure to the biotech sector with $3.1 billion in assets. The ETF has delivered strong year-to-date performance of 33.68% and one-year returns of 43.62%, though it carries higher risk with a beta of 0.68 and standard deviation of 20.77%. FBT received a Zacks ETF Rank of 2 (Buy) and is compared to competitors XBI and IBB, which have larger asset bases and lower expense ratios.

Zacks Investment Research

3 Stocks to Watch Following Guidance Upgrades

Three major healthcare companies—Illumina, Tempus AI, and Novartis—raised their FY26 guidance following positive Q3 earnings results. Illumina reported 4.2% YoY revenue growth driven by strong clinical demand and NovaSeq X placements. Tempus AI delivered record revenue with 23% YoY growth, particularly strong in its Data & Applications segment. Novartis improved its profitability outlook despite generic competition pressures.

Zacks Investment Research

Why Illumina (ILMN) is a Top Growth Stock for the Long-Term

Zacks Premium offers investment research tools including the Zacks Rank and Style Scores to help investors identify high-performing stocks. The Style Scores rate stocks on value, growth, and momentum characteristics, with the VGM Score combining all three methodologies. Illumina (ILMN) is highlighted as a stock to watch with a #3 Hold rank and B VGM Score, featuring strong growth prospects with forecasted 11.6% year-over-year earnings growth.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Sep 23, 20082-for-1forward split